Unknown

Dataset Information

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer.


ABSTRACT:

Background

Adjuvant platinum-based chemotherapy is standard of care for patients with resected stage IIA/B or IIIA NSCLC. Overall survival is suboptimal due to the high metastatic potential of early-stage NSCLC and there is substantial clinical need for additional efficacious adjuvant treatment options.

Methods

PubMed (all time to 4 February 2021) and related conference databases were searched using the key search terms 'NSCLC' AND 'Adjuvant' AND 'EGFR inhibitor' OR respective aliases.

Results

The literature search identified five adjuvant phase III trials of EGFR inhibitors in early NSCLC. The earlier BR19 and RADIANT trials failed to demonstrate statistically significant improvements in either OS or DFS for gefitinib and erlotinib, respectively, compared with placeb

SUBMITTER: Melosky B 

PROVIDER: S-EPMC8600554 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature